StreetInsider.com News Articles

Kodiak Sciences Inc. (KOD) PT Raised to $126 at H.C. Wainwright

Mon, 12 Oct 2026 06:51:19 -0400

(Updated - October 12, 2026 6:51 AM EDT)

H.C. Wainwright analyst Matthew Caufield raised the price target on Kodiak Sciences Inc. (NASDAQ: KOD) to $126.00 (from $96.00) while maintaining a Buy rating.

The analyst commented: 'In attendance at the American Academy of Ophthalmology’s (AAO) 2026 Annual Meeting, held in New Orleans, Louisiana, the retinal community was excited about more than the seafood gumbo. During the Clinical Trial Updates in Retina section, Kodiak presented its Phase 3 DAYBREAK trial results in wet AMD patients, across the enhanced reformulated Zenkuda (tarcocimab tedromer, anti-VEGF) and Tabirafusp (KSI-501, anti-VEGF, anti-IL-6). Importantly, leading retinal KOLs discussed: (i)

Kodiak Sciences Inc. (KOD) PT Raised to $126 at H.C. Wainwright

Mon, 12 Oct 2026 06:51:19 -0400

(Updated - October 12, 2026 6:51 AM EDT)

H.C. Wainwright analyst Matthew Caufield raised the price target on Kodiak Sciences Inc. (NASDAQ: KOD) to $126.00 (from $96.00) while maintaining a Buy rating.

Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026

Wed, 07 Oct 2026 07:00:00 -0400

First scientific presentation of Phase 3 DAYBREAK results for Zenkuda and tabirafusp-ted in wet age-related macular degeneration scheduled for AAO 2026.

Additional presentations include Phase 3 GLOW2 data for Zenkuda in diabetic retinopathy and Phase 1b APEX data for KSI-101 in macular edema secondary to inflammation (MESI).

PALO ALTO,

Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026

Wed, 07 Oct 2026 07:00:00 -0400

First scientific presentation of Phase 3 DAYBREAK results for Zenkuda and tabirafusp-ted in wet age-related macular degeneration scheduled for AAO 2026.

Additional presentations include Phase 3 GLOW2 data for Zenkuda in diabetic retinopathy and Phase 1b APEX data for KSI-101 in macular edema secondary to inflammation (MESI).

PALO ALTO,

Form SCHEDULE 13D/A Kodiak Sciences Inc. Filed by: BAKER BROS. ADVISORS LP

Wed, 30 Sep 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260930/27129146.html

Form 4 Kodiak Sciences Inc. For: Sep 28 Filed by: Baker Brothers Life Sciences LP

Wed, 30 Sep 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260930/27129059.html

Form 4 Kodiak Sciences Inc. For: Sep 28 Filed by: Baker Brothers Life Sciences LP

Wed, 30 Sep 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260930/27129031.html

Form 4 Kodiak Sciences Inc. For: Sep 28 Filed by: Baker Brothers Life Sciences LP

Wed, 30 Sep 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260930/27128983.html

Form 4 Kodiak Sciences Inc. For: Sep 25 Filed by: PERLROTH VICTOR

Tue, 29 Sep 2026 19:44:00 -0400

si-local-file:///var/storage/secattach/20260929/27123772.html

Kodiak Sciences Inc. (KOD) PT Raised to $96 at H.C. Wainwright

Tue, 29 Sep 2026 06:48:20 -0400

(Updated - September 29, 2026 6:48 AM EDT)

H.C. Wainwright analyst Matthew Caufield raised the price target on Kodiak Sciences Inc. (NASDAQ: KOD) to $96.00 (from $58.00) while maintaining a Buy rating.

The analyst commented: "Kodiak announced positive Phase 3 DAYBREAK trial one-year primary endpoint topline results in treatment-naïve wet AMD patients, for both the reformulated Zenkuda (tarcocimab tedromer, anti-VEGF) and KSI-501 (tabirafusp alfa tedromer, anti-VEGF, anti-IL-6). We were most impressed not only by both candidates meeting primary endpoint BCVA non-inferiority to aflibercept, but specifically Zenkuda’s rapid and sustained retinal drying with the majority of patients (54%) achieving 6-month dosing. That robust

Kodiak Sciences Inc. (KOD) PT Raised to $96 at H.C. Wainwright

Tue, 29 Sep 2026 06:48:20 -0400

(Updated - September 29, 2026 6:48 AM EDT)

H.C. Wainwright analyst Matthew Caufield raised the price target on Kodiak Sciences Inc. (NASDAQ: KOD) to $96.00 (from $58.00) while maintaining a Buy rating.

Kodiak Sciences Inc. (KOD) PT Lowered to $112 at Jefferies

Mon, 28 Sep 2026 13:32:54 -0400

Jefferies analyst Maury Raycroft lowered the price target on Kodiak Sciences Inc. (NASDAQ: KOD) to $112.00 (from $156.00) while maintaining a Buy rating.

The analyst comments "DAYBREAK is a major win for Zenkuda, delivering aflibercept-like efficacy, clean safety, and Q24W dosing in 54% pts under stringent retreatment criteria. While real-world durability may differ, we believe the data position Zenkuda as a potential best-in-class tx and shift the story toward BLA and commercial execution. KSI-501 also met non-inferiority, but differentiation remains unproven, leaving ALTO and MESI readouts as the key tests of the IL-6 thesis."

Kodiak Sciences Inc. (KOD) PT Lowered to $112 at Jefferies

Mon, 28 Sep 2026 13:32:54 -0400

Jefferies analyst Maury Raycroft lowered the price target on Kodiak Sciences Inc. (NASDAQ: KOD) to $112.00 (from $156.00) while maintaining a Buy rating.

4 Explosive Stories Enter the Investor Spotlight